Can-Fite BioPharma Ltd. CANF
AMEX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 5.64% | 5.64% | -26.23% | -26.23% | -23.22% |
| Total Depreciation and Amortization | -95.65% | -95.65% | -83.33% | -83.33% | 2,200.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -78.88% | -78.88% | -24.81% | -24.81% | -12.97% |
| Change in Net Operating Assets | -253.85% | -253.85% | 257.38% | 257.38% | 50.89% |
| Cash from Operations | -11.83% | -11.83% | -16.55% | -16.55% | -17.74% |
| Capital Expenditure | 0.00% | 0.00% | 0.00% | 0.00% | 75.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -133.33% | -133.33% | 0.00% | 0.00% | -33.33% |
| Cash from Investing | -133.38% | -133.38% | 0.00% | 0.00% | -33.30% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 11.83% | 11.83% | -13.18% | -13.18% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 11.83% | 11.83% | -6.56% | -6.56% | -- |
| Foreign Exchange rate Adjustments | -- | -- | 133.33% | 133.33% | 147.37% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -256.11% | -256.11% | -973.58% | -973.58% | 269.39% |